Tapentadol extended release: In adults with chronic pain

Drugs

Volumn 72, Issue 3, 2012, Pages 375-393

  Hoy, Sheridan M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Analgesics; Diabetic nephropathies; Opioid analgesics; Osteoarthritis; Pain; Tapentadol

Indexed keywords

ACETYLSALICYLIC ACID; CENTRAL DEPRESSANT AGENT; METOCLOPRAMIDE; MORPHINE; NAPROXEN; OMEPRAZOLE; OXYCODONE; PALEXIA; PARACETAMOL; SEROTONIN AGONIST; TAPENTADOL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; CHRONIC PAIN; CONSTIPATION; DEHYDRATION; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG UPTAKE; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; FIRST PASS EFFECT; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; INSOMNIA; KNEE OSTEOARTHRITIS; LOW BACK PAIN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NONHUMAN; PLASMA PROTEIN BINDING; POSTMARKETING SURVEILLANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN DISEASE; SOMNOLENCE; STOMACH OBSTRUCTION; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCERAL PAIN; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ADULT; ANALGESICS; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHENOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856728661     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208600-000000000-00000     Document Type: Review

References (58)

1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009 Feb; 10 (2): 113-30
2. Kumar N.WHOnormative guidelines on pain management: report of a Delphi Study to determine the need for guidelines and to identify the number and topics of guidelines that should be developed by WHO [online]. Available from URL: http://www.who.int/medicines/areas/quality-safety/delphi-study-pain-guidelines. pdf [Accessed 2011 Oct 17]
3. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63 (1): 17-32 (Pubitemid 36132511)
4. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009 Feb; 10 (2): 131-46
5. Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonists the solution to opioid side effects? Anesth Analg 2004 Jan; 98 (1): 116-22
6. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel m-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007Oct; 323 (1): 265-76 (Pubitemid 47443277)
7. Hartrick CT, Rozek RJ. Tapentadol in pain management: a m-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011; 25 (5): 359-70
8. Frampton JE. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 2010; 70 (13): 1719-43
9. Grunenthal Ltd. Palexia- SR 50mg prolonged release tablets [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/24389/SPC/ Palexia+SR+50+mg+prolongedrelease+ tablets/[Accessed 2010 Oct 12]
10. Grunenthal Ltd. Palexia- SR 100mg prolonged release tablets [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/24390/SPC/ Palexia+SR+100+mg+prolongedrelease+ tablets/[Accessed 2011 Oct 12]
11. Grunenthal Ltd. Palexia- SR 150 mg prolonged release tablets [online]. Available from URL: http://www.medicines. org.uk/EMC/medicine/24391/SPC/ Palexia+SR+150+mg+ prolonged-release+tablets/[Accessed 2011 Oct 12]
12. Grunenthal Ltd. Palexia- SR 200 mg prolonged release tablets [online]. Available from URL: http://www.medicines. org.uk/EMC/medicine/24392/SPC/ Palexia+SR+200+mg+ prolonged-release+tablets/[Accessed 2011 Oct 12]
13. Grunenthal Ltd. Palexia- SR 250 mg prolonged release tablets [online]. Available from URL: http://www.medicines. org.uk/EMC/medicine/24386/SPC/ Palexia+SR+250+mg+ prolonged-release+tablets/[Accessed 2011 Oct 12]
14. Janssen Pharmaceuticals Inc. Nucynta- ER (tapentadol) extended-release oral tablets C-II: prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/200533s000lbl.pdf [Accessed Oct 6]
15. Schrö der W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010 Sep; 14 (8): 814-21
16. Schrö der W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011 Apr; 337 (1): 312-20
17. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010 Sep; 14 (8): 781-3
18. Pergolizzi J, Alegre C, Blake D, et al. Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pain Pract. Epub 2011 Jul 29
19. Oh C, Rengelshausen J, Mangold B, et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther 2010 Oct; 48 (10): 678-87
20. Biondi D, Xiang J, Etropolski M, et al. A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies [abstract no. 319]. J Pain 2011; 12 (4 Suppl.): P55
21. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and activecontrolled phase III study. Clin Drug Invest 2010; 30 (8): 489-505
22. Grü nenthal GmbH. A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee [Clinical Trials.gov identifier NCT00486811]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/[Accessed 2011 Sep 30]
23. Therapeutic Goods Administration. Australian public assessment report for tapentadol. Woden (ACT): Therapeutic Goods Administration, 2011 Feb [online]. Available from URL: http://www.tga.gov.au/pdf/auspar/auspar-palexia-sr. pdf [Accessed 2012 Jan 27]
24. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010 Aug; 11 (11): 1787-804
25. Etropolski M, Shapiro D, Okamoto A, et al. An analysis of changes in vital signs and electrocardiogram measurements with tapentadol prolonged release (PR) treatment [abstract no. F644]. European J Pain Suppl 2011 Sep; 5 (1): 181-182. Plus poster presented at the 7th Congress of the European Federation of the International Association for the Study of Pain (IASP) Chapters (EFIC); 2011 Sep 21-24; Hamburg
26. Schwartz S, Etropolski M, ShapiroDY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebocontrolled trial. Curr Med Res Opin 2011 Jan; 27 (1): 151-62
27. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010 Sep-Oct 31; 10 (5): 416-27
28. Smit JW, Hä ufel T, Ravenstijn P, et al. Pharmacokinetics of tapentadol in healthy elderly and young adult subjects [abstract no. 96]. J Clin Pharmacol 2010; 50: 1079. Plus poster presented at the 39th Annual Meeting of the American College of Clinical Pharmacology (ACCP); 2010 Sep 12-14; Baltimore (MD)
29. Smit JW, Brett M, Kleideiter E, et al. Pharmacokinetics of tapentadol in subjects with varying degrees of hepatic impairment [abstract no. 94]. J Clin Pharmacol 2010; 50: 1078. Plus poster presented at the 39th Annual Meeting of the American College of Clinical Pharmacology (ACCP); 2010 Sep 12-14; Baltimore (MD)
30. Smit JW, Kleideiter E, Brett M, et al. Pharmacokinetics of tapentadol in subjects with varying degrees of renal impairment [abstract no. 95]. J Clin Pharmacol 2010; 50: 1079. Plus poster presented at the 39th Annual Meeting of the American College of Clinical Pharmacology (ACCP); 2010 Sep 12-14; Baltimore (MD)
31. Smit JW, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy 2010 Jan; 30 (1): 25-34
32. Etropolski MS, Okamoto A, Shapiro DY, et al. Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician 2010 Jan; 13 (1): 61-70
33. Johnson & Johnson Pharmaceutical Research & Development, LLC. An open-label extension study with flexible dosing of extended-release (ER) tapentadol (CG5503) to treat patients with moderate to severe chronic pain [ClinicalTrials. gov identifier NCT00487435]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2011 Sep 15]
34. Johnson & Johnson Pharmaceutical Research & Development, LLC.Open-label extension, single-arm, flexible-dosing, phase 3 study with tapentadol extended-release (ER) in subjects with moderate to severe chronic pain [online]. Available from URL: http://filehosting.pharmacm.com/Download Service.ashx?client=CTR-JNJ-6051&studyid=70&filename= CR013567-CSR.pdf [Accessed 2011 Sep 15]
35. Hä ussler J, Kuperwasser B, Kelly K, et al. Influence of discontinuation rates and imputation methods on the efficacy results of tapentadol ER in a randomized, double-blind, placebo- and active-controlled trial in patients with chronic osteoarthritis knee pain [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 283. Plus poster presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR); 2009 Jun 10-13; Copenhagen
36. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release (PR) based on prior opioid experience in patients with chronic osteoarthritis knee pain [abstract no. THU0431]. Ann Rheum Dis 2010; 69 Suppl. 3: 287
37. Etropolski MS, Shapiro DY, Leslie H, et al. Analysis of efficacy and safety of tapentadol extended release (ER) for chronic low back pain based on prior opioid experience [abstract no. 707]. Eur J Pain 2009; 13 Suppl. 1: S203-4
38. Shapiro DY, Etropolski M, Lange B, et al. Tapentadol prolonged release (PR) for painful diabetic peripheral neuropathy (DPN): efficacy and safety by prior opioid experience and dose category [abstract no. 292]. Eur J Pain Suppl 2010 Apr; 4 (1): 84
39. Etropolski M, Kleinert R, Shapiro DY, et al. Health-related outcomes associated with tapentadol extended release (ER) treatment for the management of painful diabetic peripheral neuropathy (DPN): results of a randomizedwithdrawal phase 3 trial [abstract no. O-0221]. Can J Diabetes 2009; 33 (3): 193
40. Okamoto A, Shapiro DY, Lange B, et al. Health status (EuroQol-5 Dimension [EQ-5D]) in patients with painful diabetic peripheral neuropathy (DPN) treated with tapentadol extended release (ER): results of a randomizedwithdrawal phase 3 study [abstract no. D-0831]. Can J Diabetes 2009; 33 (3): 245
41. McCann B, Lange R, Wagner B, et al. Patient global impression of change results from a 1-year open-label extension study of tapentadol extended release in patients with chronic osteoarthritis or low back pain [abstract no. 950]. Arthritis Rheum 2010; 62 Suppl. 10: S394. Plus poster presented at the 74th Annual Scientific Meeting of the American College of Rheumatology/45th Annual Scientific Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP); 2010 Nov 6-11; Atlanta (GA)
42. Kuperwasser B, McCann B, Van Hove I, et al. Health status of patients who received tapentadol prolonged release during an open-label extension study [abstract no. 337]. Osteoarthritis Cartilage 2010; 18 Suppl. 2: s149. Plus poster presented at the Osteoarthritis Reseach Society International (OARSI) 2010 World Congress on Osteoarthritis; 2010 Sep 23-23; Brussels
43. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010 Jun; 27 (6): 381-99
44. Steigerwald I, Schutter U, Ritchie M, et al. Effectiveness and safety of tapentadol prolonged release (PR) for the management of severe, chronic osteoarthritis knee pain [abstract no. FRI0128 plus poster]. Ann Rheum Dis 2011; 70 Suppl. 3: 387
45. Steigerwald I, Kress HG, Kern U, et al. Effectiveness of tapentadol prolonged release (PR) for the management of severe, chronic low back pain with or without a neuropathic component [abstract no. 061 plus poster]. NWAC World Anesthesia Congress; 2011 Apr 11-15; Rome
46. Steigerwald I, Hans G, Schä fer M, et al. Equipotency of tapentadol prolonged release (PR) and World Health Organization (WHO) Step III opioids in patients with severe, chronic low back pain [abstract no. 062 plus poster]. NWAC World Anesthesia Congress; 2011 Apr 11-15; Rome
47. Steigerwald I, Sprü nken A, Lahne U, et al. Effectiveness of tapentadol prolonged release (PR) and equipotency of tapentadol PR compared with World Health Organization (WHO) Step III opioids in patients with severe, chronic osteoarthritis (OA) knee pain [abstract]. 10th Annual ASRA Pain Medicine Meeting & Workshops; 2011 Nov 17-20; New Orleans (LA)
48. Hauschke D, Pigeot I. Establishing efficacy of a new experimental treatment in the 'gold standard' design. Biom J 2005 Dec; 47 (6): 782-6; discussion 787-98 (Pubitemid 43037324)
49. Biondi D, Xiang J, Etropolski M, et al. A post hoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) versus oxycodone controlled release (CR) in patients 75 years of age [abstract no. 320]. J Pain 2011; 12 (4 (Suppl. 1): 56
50. Biondi D, Xiang J, Lange R, et al. Tapentadol extended release versus oxycodone controlled release for management of chronic low back or osteoarthritis pain: analyses of study discontinuations due to constipation, nausea, or vomiting [abstract no. 265]. J Pain 2010 May 6; 11 (4 Suppl.): S42
51. Blondi D, Xiang J, Lange R, et al. Tolerability of tapentadol extended release versus oxycodone controlled release in elderly patients with chronic low back or osteoarthritis pain in a 1-year safety study [abstract]. Der Schmerz 2010; 24 (Suppl. 1): 92
52. Biondi D, Xiang J, Vorsanger G, et al. Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: influence of prior opioid experience on study discontinuations due to constipation, nausea, or vomiting [abstract no. 267]. J Pain 2010; 11 (4 Suppl.): S42
53. Data on file, Grü nenthal GmbH 2011
54. Grü nenthal GmbH. European decentralised procedure positively concluded for Grü nenthal's tapentadol [media release]. 2010 Sep 16 [online]. Available from URL: http://grunenthal.com/[Accessed 2011 Oct 12]
55. Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011 Oct; 27 (10): 1907-30
56. Cepeda MS, Sutton A, Weinstein R, et al. Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. Clin J Pain 2012 Jan; 28 (1): 8-13
57. Hertel N, Ikenberg R, Fricke FU, et al. Cost-effectiveness of tapentadol prolonged-release (PR) compared to oxycodone and morphine in patients with chronic moderate to severe non-cancer pain in Sweden [abstract no. PSY34]. Value Health 2010; 13 (7): A466. Plus poster presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2010 Nov 6-9; Prague
58. Obradovic M, Ikenberg R, Hertel N, et al. Cost-effectiveness of tapentadol prolonged-release (PR) compared to oxycodone controlled release (CR) in patients with chronic severe non-cancer pain in Ireland [abstract no. PSY31]. Value Health 2011; 14 (7): A415-6